CSL: The Crown Jewel of the ASX
CSL Limited is widely considered the highest-quality business listed on the Australian Securities Exchange. A global leader in blood plasma products, vaccines, and kidney disease therapy (through Vifor Pharma), CSL has compounded earnings at over 15% annually for more than two decades — through recessions, COVID, and multiple market cycles.
The Graham Number Problem
CSL's Graham Number is approximately $85. The current price is approximately $280. That is 3.3× the Graham Number.
Immediately this tells you: do not use Graham Number to value CSL. The formula penalises businesses where value is intangible — patents, regulatory approvals, collection networks — not physical assets.
This is not a flaw in the business. It is a feature. Graham Number was designed for steel mills and banks, not biotechnology royalties.
Why DCF Is the Correct Tool
CSL's value is in its durable competitive advantages: - Near-monopoly position in plasma-derived therapies (3 global players) - Plasma collection networks take 20+ years and billions to build — impossible to replicate - Inelastic demand: patients need immunoglobulin therapies regardless of economy - Vaccines division (Seqirus): #2 influenza vaccine supplier globally
These advantages generate cash, and DCF captures cash. Let's run it.
DCF Valuation — Three Scenarios
| Scenario | FCF Growth | Discount Rate | DCF Value (AUD) |
|---|---|---|---|
| Bull | 15% → 8% terminal 3% | 10% | ~$340 |
| Base | 12% → 6% terminal 3% | 10% | ~$268 |
| Bear | 6% → 2% terminal 2% | 10% | ~$185 |
At a current price of ~$280, the market is pricing CSL somewhere between the base and bull scenarios. The stock is fairly valued, not obviously cheap, not obviously expensive for a business of this quality.
AI Stock Reports: full CSL analysis in your hands
Pro users get AI-generated reports with business quality assessment, risk factors, valuation commentary, and buy/hold/sell guidance — for CSL and any other stock.
Start Free Trial — Pro Standard from $7/moStructural Advantages That Justify the Premium
Near-monopoly in plasma-derived therapies: The immunoglobulin market has 3 global suppliers (CSL, Grifols, Takeda). Building a competing plasma collection network from scratch costs $10B+ and takes 20 years. This moat is essentially unassailable.
Inelastic demand: Immunodeficiency patients need IVIG therapy regardless of economic conditions or drug pricing legislation. This is not discretionary.
Vifor integration: The $12B Vifor acquisition (kidney disease) diversified revenue away from plasma dependency and adds growing non-plasma biologics to the portfolio.
Vaccine platform: Seqirus is the #2 global influenza vaccine maker with pandemic-response capabilities that command government contracts and regulatory goodwill.
The Quality Premium Debate
For exceptional businesses, paying above Graham Number is rational when three conditions are met:
- The growth rate is genuinely high and sustainable (CSL: ✓ 15%+ for 20+ years)
- Returns on capital remain well above the cost of capital (CSL ROE: ~28% vs 10% WACC: ✓)
- The competitive moat is durable and widening (CSL plasma network: ✓)
CSL passes all three tests convincingly. The question is simply the price you pay.
When to Buy CSL
Below $240 provides genuine margin of safety against the base DCF case. The $200-220 range — seen during COVID disruptions and general market selloffs — has historically been an exceptional entry point.
Strategy: Add CSL to your Value Calc watchlist, set a target buy price of $220-240, and wait. Market corrections regularly deliver quality businesses at sensible prices for those who did the work in advance.